人胚胎干细胞程序降温保存的实验研究

本文采用升降式程序降温仪对人胚胎于细胞进行了程序降温保存,并探讨和比较了降温速率、置核温度、保护剂和投入液氮前温度对冻存复苏后胚胎干细胞的存活率、活力及分化特性的影响。结果表明:采用Me_2SO 血清 DMEM(体积比为1∶3∶6)的保护剂,从0℃开始,以0.5℃/min的速率对细胞悬液降温;至-10℃时对其进行置核,并于-35℃时将其快速投入液氮中保存,复温后效果最佳。冻存复温后细胞存活率可达81.8%,复苏后的胚胎干细胞形态和集落生长方式都与冻前的生长形态相同,且胚胎干细胞标志之一碱性磷酸酶(AKP)反应阳性,同时染色体组型仍正常。     

单抗清除瘤细胞后人骨髓的冷冻保存研究

本实验研究了用CD10类单克隆抗体55(McAb55)与兔补体结合的方法清除骨髓中普通型急性淋巴细胞白血病抗原(CALLA)阳性细胞后骨髓的冷冻保存问题。结果表明:①清除处理对人骨髓的粒单系集落培养(GM-CFU-C)无明显影响;②经过冷冻贮存的样品的GM-CFU-C少于未经冻存的样品;③清除瘤细胞后的样品冻存后与未经清除处理的正常骨髓样品冻存后的GM-CFU-C无显著差别;④影响冷冻保存后骨髓GM-CFU-C的重要因素是冷冻速率;⑤在本实验条件下以0.5℃/min速率降温效果最佳,冻后GM-CFU-C无改变,冷冻损伤主要发生于-40℃以前,降温至-40℃或～80℃后再快速降温影响不明显。此研究为用McAb55加兔补体清除骨髓中CALLA阳性细胞后骨髓的冷冻保存提供了依据。     

人胚胎干细胞程序降温保存的实验研究

本文采用升降式程序降温仪对人胚胎干细胞进行了程序降温保存,并探讨和比较了降温速率、置核温度、保护剂和投入液氮前温度对冻存复苏后胚胎干细胞的存活率、活力及分化特性的影响。结果表明：采用Me2SO 血清 DMEM(体积比为1：3：6)的保护剂,从0℃开始,以0．5℃／min的速率对细胞悬液降温;至-10℃时对其进行置核,并于-35℃时将其快速投入液氮中保存,复温后效果最佳。冻存复温后细胞存活率可达81．8％,复苏后的胚胎干细胞形态和集落生长方式都与冻前的生长形态相同,且胚胎干细胞标志之一碱性磷酸酶(AKP)反应阳性,同时染色体组型仍正常。     

瘦素诱导体外培养大鼠脂肪间充质干细胞凋亡

为观察瘦素诱导体外培养大鼠脂肪间充质干细胞凋亡的作用, 采用胶原酶消化法分离培养大鼠附睾脂肪垫间充质干细胞, 第3代细胞用于实验。细胞免疫荧光化学方法鉴定CD105、Vimentin表达阳性率约80%以上, 10-6 mol/L的瘦素作用细胞48 h、72 h后激光共聚焦显微镜观察分别可见早期及中晚期特征表现; 0 mol/L、10-8 mol/L、10-7 mol/L、10-6 mol/L瘦素分别作用于细胞48 h后, 应用AnnexinⅤ/PI双染色法流式细胞仪检测早期凋亡率分别为2.50%±0.72%、6.78%±1.99%、11.99%±1.58%、17.93%±4.82% (P<0.05); 随着瘦素浓度的增加和作用时间的延长, Caspase-3的活性逐渐增高, 至48 h时达到高峰。说明瘦素可以直接诱导脂肪间充质干细胞凋亡, 从数量上减少脂肪组织的含量。     

血小板第四因子对脐血CD34+细胞趋化作用的研究

目的 :研究PF4及其小肽PF417 70对新鲜脐血CD34+细胞的趋化作用及对粘附分子表达的影响。方法 :采用免疫磁珠法 (MACS)分选CD34+细胞 ,利用Transwell穿孔板测定PF4对CD34+细胞的趋化作用 ;流式细胞仪检测免疫荧光标记的粘附分子及CXCR4的表达。结果 :①PF4对脐血CD34+细胞有趋化作用 ,PF4组的趋化百分比为 15 7.43%± 5 0 .0 6 %(P <0 .0 5 ) ,PF417 70组为 187.0 2 %± 10 .6 9%(P <0 .0 5 )。②PF4作用于CD34+细胞时 ,CD49d和CXCR 4表达增加 ,对其它粘附分子CD31,CD44 ,CD11a ,CD6 2 p ,CD6 2E的表达没有影响。 结论 :PF4对脐血CD34+细胞有趋化作用 ,促进整合素CD49d及CXCR4的表达 ,PF4有助于脐血干细胞的归巢。     

用悬浮搅拌培养体系体外大量扩增人脐血造血干/祖细胞

目的 :建立一种简便、有效的脐血造血干 /祖细胞体外大量扩增培养体系。方法 :淋巴细胞分离液分离的脐血单个核细胞在SCF ,IL - 3,IL - 6三种细胞因子的作用下 ,于悬浮搅拌培养体系中培养 ,分析其总细胞数、CFU -GM、CD34+ 细胞的扩增倍数。结果 :脐血单个核细胞在悬浮搅拌培养体系中培养 12天后 ,其总细胞数、CFU -GM、CD34+ 细胞的扩增倍数分别为 6 .31± 1.5 2 ,2 0 .6 3± 1.5 4和 7.11± 1.12。结论 :悬浮搅拌培养体系是脐血造血干 /祖细胞体外大量扩增的有效培养体系。     

人核糖核酸抑制因子基因在人脐血干细胞中的转染表达及对小鼠黑色素瘤基因治疗的研究

探讨人核糖核酸抑制因子 (hRI)基因在人脐血干细胞中的转染及表达情况 ,及转染后对小鼠B16黑色素瘤生长的影响。用免疫磁珠分离系统 (MACS)分离纯化人脐血CD34⁺ 细胞后 ,用制备的含hRI基因的逆转录病毒上清转染脐血CD34⁺ 细胞 ,采用克隆形成法和PCR法检测转染效率 ,Western blot和免疫荧光法检测基因表达 ,同时观察RI对荷瘤C57BL小鼠B16黑色素瘤生长的影响。应用MACS能高度纯化人脐血CD34⁺ 细胞 ,使分选后的脐血CD34⁺ 细胞纯度平均达96.15%。hRI基因能够转染到脐血CD34⁺ 细胞上 ,转染效率达 35% ,Western blot和免疫荧光检测转染后CD34⁺ 细胞hRI基因有阳性表达。经转hRICD34⁺ 细胞治疗 ,使小鼠B16黑色素瘤的生长速度减慢 ,成瘤率和瘤重降低 ,成瘤潜伏期延长。     

雨生红球藻FACHB-712营养细胞和厚壁孢子低温保藏效果及优化

以高产虾青素的雨生红球藻（Haematococcus pluvialis Flotow）FACHB-712藻株为材料,研究2种细胞形态（营养细胞和厚壁孢子）在低温保藏下的复苏率及其差异原因。结果显示,采用两步法（先预冻降温后再投入液氮中）冻存其营养细胞,在不同冻存条件下,其存活率均低于5%,以10%甘油作为保护剂、冻存速率为0.5℃/min、预冻温度为-40℃、保留30 min,然后再投入液氮罐（-196℃）中保藏,其存活率可达到13.3%。采用两步法冻存厚壁孢子,其复苏存活率高达66.13%,复苏萌发后细胞的生长特性、虾青素含量与液氮保藏前无明显差异（P > 0.05）。对液氮保藏前后藻细胞形态和超微结构观察结果表明,超低温保藏后,营养细胞的结构受到较大损伤,而厚壁孢子受到的损伤相对较小。当添加不同保护剂后,直接将厚壁孢子分别冻存在-20℃、-80℃低温及液氮中,发现-80℃低温冻存处理组的复苏存活率相对较高,可达27%。研究表明采用两步法先预冻降温后再投入液氮中冻存厚壁孢子,是长期保藏雨生红球藻FACHB-712的最佳方法,也可采用一步法将厚壁孢子冻存于-80℃冰箱中。     

仿刺参(Apostichopus japonicus)肠道源植物乳杆菌(Lactobacillus plantarum) HY21的生长及益生特性分析

【目的】在仿刺参(Apostichopus japonicus)健康养殖中为了寻找具有良好耐受性、益生性、安全性的益生菌,本研究从仿刺参肠道内容物中分离获得一株植物乳杆菌(Lactobacillus plantarum) HY21,对其益生潜能进行评价。【方法】利用摇瓶发酵培养、应用环境因子模拟试验、抗生素药敏测试等方法,分析L. plantarum HY21的生长特性、产酸性能、发酵液的抗氧化性质和对水产致病菌的抑制作用;检测菌体的疏水性、自聚性和共聚性、黏附力和药物敏感性,以及对应用环境因子的耐受性。【结果】L. plantarum HY21摇瓶发酵培养温度30℃、初始pH 8.0,于2-10 h为对数生长期,发酵18 h后pH达到最低3.6;发酵液对溶藻弧菌的抑菌直径达到(13.96±0.30) mm,对1,1-二苯基-2-三硝基苯肼(1,1-diphenyl-2-trinitrophenylhydrazine, DPPH)自由基清除率达到95.45%±1.56%;L. plantarum HY21的疏水率为60.42%±2.78%、自聚率为22.69%±1.36%,与溶藻弧菌共聚率为27.98%±1.45%;对体表和肠道黏液蛋白的黏附量分别达到(1.66±0.01)×10⁶ CFU/mL和(1.23±0.15)×10⁶ CFU/mL;对13种常见的抗菌药物均表现敏感;菌体在模拟胃肠液(pH 3.0, pH 6.8)中孵育3 h存活率均可达99%以上,在10%鱼胆汁溶液中孵育3 h存活率达到68.11%±7.98%,在3%海盐溶液中孵育16 h存活率达到97.58%±7.14%。【结论】L. plantarum HY21具有良好的定殖作用、抑菌作用、抗氧化作用等益生特性,而且在应用环境中具有高存活率和高安全性,可以作为一株新的水产益生菌,为开发水产益生菌制剂提供科学理论依据。     

长期肾移植受者外周血B淋巴细胞亚群分布特征

摘要 目的：观察移植肾功能稳定的长期受者（>10年）外周血B细胞亚群分布特征及其相关因素。方法：54名肾移植受者接受流式细胞仪检查,测算外周血总B细胞、未转化记忆B细胞、转化记忆B细胞、双阴性B细胞（CD19⁺CD27^-IgD^-）比例及数量（个/微升）。患者均服用包括环孢霉素的免疫抑制治疗。术后时间16.33±5.98年,GFR：91.63±11.28 mL/min/1.73 m²。结果：1长期肾移植患者外周血B细胞中幼稚B细胞最多（37.92% ± 22.06%）,未转化记忆B细胞最少(16.23% ± 11.10%)。B细胞亚群数量与白细胞总数、中性粒细胞比例等相关。2 以上述条件为控制因素行相关分析,转化记忆B细胞比例和GFR相关（r=-0.279,P=0.045）,双阴性B细胞数量和环孢霉素浓度相关（r=-0.300,P=0.029）。线性回归显示双阴性B细胞数目与环孢霉素浓度相关（R²=0.123,P=0.049）。3按GFR将患者分为肾功能减退组（GFR<90 mL/min/1.73 m²,n=19）和肾功能正常组（GFR≥90 mL/min/1.73 m²,n=35）。前者转化记忆B细胞比例显著升高（23.61% ± 10.96% vs.17.48%±8.91%,P=0.030）。按环孢霉素谷浓度将患者分为低浓度组（<64 mmol/L,n=28）和高浓度组（≥64 mmol/L,n=26）,前者双阴性B细胞数量显著升高（13.74±10.70 vs. 8.14±6.72/μL,P=0.027）。转化记忆B细胞比例与GFR分组相关（r=-0.326,P=0.018）,双阴性B细胞数量和环孢霉素浓度分组相关（r=-0.350,P=0.01）。结论：移植肾功能稳定的长期存活受者（>10年）外周血幼稚B细胞较多。转化记忆B细胞增多与移植肾功能减退相关,增多的双阴性B细胞和低孢霉素浓度治疗相关。     

Cryopreservation of umbilical cord blood: 2. Tolerance of CD34(+) cells to multimolar dimethyl sulphoxide and the effect of cooling rate on recovery after freezing and thawing

Cryopreservation protocols for umbilical cord blood have been based on methods established for bone marrow (BM) and peripheral blood stem cells (PBSC). The a priori assumption that these methods are optimal for progenitor cells from UCB has not been investigated systematically. Optimal cryopreservation protocols utilising penetrating cryoprotectants require that a number of major factors are controlled: osmotic damage during the addition and removal of the cryoprotectant; chemical toxicity of the cryoprotectant to the target cell and the interrelationship between cryoprotectant concentration and cooling rate. We have established addition and elution protocols that prevent osmotic damage and have used these to investigate the effect of multimolar concentrations of Me(2)SO on membrane integrity and functional recovery. We have investigated the effect of freezing and thawing over a range of cooling rates and cryoprotectant concentrations. CD34(+) cells tolerate up to 60 min exposure to 25% w/w (3.2M) Me(2)SO at +2 degrees C with no significant loss in clonogenic capacity. Exposure at +20 degrees C for a similar period of time induced significant damage. CD34(+) cells showed an optimal cooling range between 1 degrees C and 2.5 degrees C/min. At or above 1 degrees C/min, increasing the Me(2)SO concentration above 10% w/w provided little extra protection. At the lowest cooling rate tested (0.1 degrees C/min), increasing the Me(2)SO concentration had a statistically significant beneficial effect on functional recovery of progenitor cells. Our findings support the conclusion that optimal recovery of CD34(+) cells requires serial addition of Me(2)SO, slow cooling at rates between 1 degrees C and 2.5 degrees C/min and serial elution of the cryoprotectant after thawing. A concentration of 10% w/w Me(2)SO is optimal. At this concentration, equilibration temperature is unlikely to be of practical importance with regard to chemical toxicity.     

Analysis and cryopreservation of hematopoietic stem and progenitor cells from umbilical cord blood

BACKGROUND: Umbilical cord blood (UCB) is an important source of hematopoietic stem and progenitor cells (HSC/HPC) for the reconstitution of the hematopoietic system after clinical transplantation. Cryopreservation of these cells is critical for UCB banking and transplantation as well as for research applications by providing readily available specimens. The objective of this study was to optimize cryopreservation conditions for CD34+ HSC/HPC from UCB. METHODS: Cryopreservation of CD34+ HSC/HPC from UCB after mononuclear cell (MNC) preparation was tested in a research-scale setup. Experimental variations were concentration of the cryoprotectant, the protein additive and cell concentration. In addition, protocols involving slow, serial addition and removal of DMSO were compared with standard protocols (fast addition and removal of DMSO) in order to avoid osmotic stress for the cryopreserved cells. Viability and recoveries of MNC, CD34+ cells and total colony-forming units (CFU) were calculated as read-outs. In addition, sterility testing of the collected UCB units before further processing was performed. RESULTS: The optimal conditions for cryopreservation of CD34+ HPC in MNC preparations were 10% DMSO and 2% human albumin at high cell concentrations (5 x 10(7) MNC/mL) with fast addition and removal of DMSO. After cryopreservation using a computer-controlled freezer, high viabilities (89%) and recoveries for CD34+ cells (89%) as well as for CFU (88%) were observed. Microbial contamination of the collected UCB samples was reduced to a rate of 6.4%. DISCUSSION: Optimized cryopreservation conditions were developed for UCB MNC in respect of the composition of the cryosolution. In addition, our results showed that fast addition of DMSO is essential for improved cryopreservation and post-thaw quality assessment results, whereas the speed of DMSO removal after thawing has little influence on the recoveries of CD34+ cells and CFU.     

Evaluation of trehalose and sucrose as cryoprotectants for hematopoietic stem cells of umbilical cord blood

Bone marrow transplantation (BMT) is a therapeutic procedure that involves transplantation of hematopoietic stem cells (HSC). To date, there are three sources of HSC for clinical use: bone marrow; mobilized peripheral blood; and umbilical cord blood (UCB). Depending on the stem cell source or type of transplantation, these cells are cryopreserved. The most widely used cryoprotectant is dimethylsulfoxide (Me₂SO) 10% (v/v), but infusion of Me₂SO-cryopreserved cells is frequently associated with serious side effects in patients. In this study, we assessed the use of trehalose and sucrose for cryopreservation of UCB cells in combination with reduced amounts of Me₂SO. The post-thawed cells were counted and tested for viability with Trypan blue, the proportion of HSC was determined by flow cytometry, and the proportion of hematopoeitic progenitor cells was measured by a colony-forming unit (CFU) assay. A solution of 30 mmol/L trehalose with 2.5% Me₂SO (v/v) or 60 mmol/L sucrose with 5% Me₂SO (v/v) produced results similar to those for 10% (v/v) Me₂SO in terms of the clonogenic potential of progenitor cells, cell viability, and numbers of CD45⁺/34⁺ cells in post-thawed cord blood cryopreserved for a minimum of 2 weeks. Thus, cord blood, as other HSC, can be cryopreserved with 1/4 the standard Me₂SO concentration with the addition of disaccharides. The use of Me₂SO at low concentrations in the cryopreservation solution may improve the safety of hematopoietic cell transplantation by reducing the side effects on the patient.     

A novel high-yield volume-reduction method for the cryopreservation of UC blood units

BACKGROUND: For the application of umbilical cord blood (UCB) units as hematopoietic grafts, a dose of 3.7 x 10(7) nucleated cells (NC)/kg body weight is required. NC can be lost during volume-reduction processing and during thawing. A novel modification of the double-processing protocol with the aim of minimizing NC loss is described and evaluated. METHODS: One-hundred and fifty UCB were collected. The volume was reduced by a centrifugation step following double-processing in the presence of 2% HES 200/0.5. Pre- and post-processing cell counts and platelet parameters were measured with an automatic counter. The number of viable CD34+ hemopoietic stem cells was measured by flow cytometry. In 25 of the samples, colony-forming units (CFU) were also determined. The same samples were thawed 6 months after cryopreservation and re-evaluated. RESULTS: The volume was reduced to 6 +/- 1.5 mL. The recovery of NC, MNC, CD34+ hemopoietic stem cells, RBC depletion and CFU following double-processing was 93.6 +/- 3.2%, 95.8 +/- 2.2%, 98.4 +/- 1.5%, 96.8 +/- 1.1% and 107.1 +/- 6.1% (for 25 samples), respectively. The post-thaw recoveries of NC, MNC, CD34+ hemopoietic stem cells and CFU (for 25 samples) were 78.6 +/- 5.4%, 90.8 +/- 4.4%, 96.4 +/- 2.5%, 89.1 +/- 4.1%, respectively. No post-thaw cell aggregation was observed. A significant (P<0.05) post-thaw loss of platelets and signs of platelet activation was observed. DISCUSSION: The protocol uses non-expensive equipment and clinically approved materials and results in samples that can be used in patients with a mean weight of 32.7 kg.     

Evaluation of a clinical-grade,cryopreserved, ex vivo-expanded stem cell product from cryopreserved primary umbilical cord blood demonstrates multilineage hematopoietic engraftment in mouse xenografts

Background aimsAllogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative therapy for a wide range of malignant and genetic disorders of the hematopoietic and immune systems. Umbilical cord blood (UCB) is a readily available source of stem cells for allo-HSCT, but the small fixed number of hematopoietic stem and progenitor cells (HSPCs) found in a single unit limits its widespread use in adult recipients. The authors have previously reported that culturing UCB-CD34⁺ cells in serum-free media supplemented with a combination of cytokines and the histone deacetylase inhibitor valproic acid (VPA) led to expansion of the numbers of functional HSPCs. Such fresh expanded product has been advanced to the clinic and is currently evaluated in an ongoing clinical trial in patients with hematological malignancies undergoing allo-HSCT. Here the authors report on the cryopreservation of this cellular product under current Good Manufacturing Practice (cGMP).MethodscGMP VPA-mediated expansion was initiated with CD34⁺ cells isolated from cryopreserved primary UCB collections, and the functionality after a second cryopreservation step of the expanded product evaluted in vitro and in mouse xenografts.ResultsThe authors found that the cryopreserved VPA-expanded grafts were characterized by a high degree of viability, retention of HSPC phenotypic subtypes and maintenance of long-term multilineage repopulation capacity in immunocompromised mice. All cellular and functional parameters tested were comparable between the fresh and cryopreserved VPA-expanded cellular products.ConclusionsThe authors’ results demonstrate and support the practicality of cryopreservation of VPA-expanded stem cell grafts derived from UCB-CD34⁺ cells for clinical utilization.     

Cryopreservation of vascular endothelial cells as isolated cells and as monolayers

This paper reports the cryopreservation of an immortalized human endothelial cell line (ECV304), either as a single cell suspension or as a confluent layer on microcarrier beads. Cell suspensions were exposed to 10% w/w dimethyl sulfoxide in a high-potassium solution (CPTes) at 0 degrees C. The cells were then cooled to -60 degrees C at controlled rates between 0.3 and 500 degrees C/min and stored below -180 degrees C. Samples were thawed in a 37 degrees C water bath and the cryoprotectant was removed by serial dilution at 22 degrees C over 6 min. The recovery of cell suspensions was assayed by culturing aliquots in 24-well plates for 7-9 days and counting the number of colonies that contained >25 cells. Maximum survival was 45-50% at cooling rates of 0.3, 1.0, and 10 degrees C/min, but decreased to 20% at 50 degrees C/min and to <1% at 500 degrees C/min. Biosilon microcarrier beads were used for the attached cells. Confluent beads were cryopreserved by exactly the same technique and cell function was assayed by measuring active amino acid (leucine) transport at 37 degrees C. Control, untreated confluent beads gave approximately 73% of control uptake and negative controls (frozen without cryoprotectant) gave approximately 4% uptake. The cells attached to beads showed percentage uptakes that were numerically similar to the survival of cells in suspension at cooling rates between 10 and 500 degrees C/min, but at lower cooling rates the recovery of attached cells increased to 70% at 1 degrees C/min and to 85% at 0.3 degrees C/min. These results indicate a marked difference in the effect of cooling rate on ECV304 cells depending upon attachment.     

In vitro characterization of two lineage-negative CD34+ cell-enriched hematopoietic cell populations from human UC blood

BACKGROUND: During the last few years there has been increasing interest, from both biologic and clinical points of view, in the ex vivo expansion of umbilical cord blood (UCB)-derived hematopoietic cells. This has brought about the need to characterize different cell populations present in UCB, and to explore different ex vivo approaches for the culture, expansion and biologic manipulation of these cells. METHODS: By using a negative-selection method, two UCB cell populations were obtained that were enriched for primitive lineage-negative (Lin-) cells, including those expressing the CD34 Ag (35-93% of the total cells in each fraction). Population I was enriched for CD34+ Lin- cells, whereas population II was enriched for CD34+ CD38- Lin- cells. Both populations were cultured in serum-free liquid cultures supplemented with different combinations of early and late-acting recombinant cytokines (all of them added at 10 ng/mL). Every 5-7 days proliferation, expansion and differentiation capacities of each population were determined, for a total period of 25-42 days. RESULTS: Both cell populations showed extensive proliferation and expansion capacities; however, population II [2300- and 232-fold increase in nucleated and colony-forming cell (CFC) numbers, respectively] was clearly superior in both parameters compared with population I (1120- and 20-fold increase in nucleated and CFC numbers, respectively). Depending on the cytokine combination used, granulocytes, macrophages and erythroblasts were preferentially produced. We also observed that both populations were highly sensitive to the inhibitory effects of tumor necrosis factor-alpha, even in the presence of stimulatory cytokines. DISCUSSION: This study demonstrates that the two progenitor cell-enriched populations obtained by negative selection possess extensive proliferation and expansion potentials in vitro, generating significant numbers of both primitive and mature cells. These cells may be a good alternative to purified CD34+ cells, obtained by positive selection, for pre-clinical and clinical protocols aimed at the ex vivo expansion of UCB cells.     

A technical bias: differences in cooling rates prevent ampoules from being a reliable index of stem cell cryopreservation in large volumes

Ampoule tests are commonly used as an index of the cryopreservation efficiency of marrow stem cells in bags. We have studied the recovery of hematopoietic progenitor cells (CFU-GM, BFUe) in 52 ampoules and compared it to the recovery in 83 standard bags. Our data showed significantly deficient CFU-GM and BFUe recoveries (respectively 47 +/- 31% and 31 +/- 30%) in ampoules when compared to bags (respectively 72 +/- 22% and 64 +/- 19%; P less than 0.001). Moreover, a good progenitor cell recovery (greater than or equal to 50%) was observed in only 46% of frozen ampoules versus 100% observed in frozen bags (P less than 0.05). We were able to relate this nonoptimal recovery to an excessively rapid freezing rate of -9 degrees C/min following the release of fusion heat which occurred in ampoules, while the freezing rate was constantly maintained at -2 degrees C/min in the corresponding bags. We therefore conclude that the cooling conditions have to be carefully controlled to ensure that the bags and ampoules are both cooled under the same conditions. Otherwise, ampoules would not be a reliable index of the true progenitor cells' cryopreservation efficiency in bags.     

Optimization of cryopreservation condition for hematopoietic stem cells from umbilical cord blood

The conditions for cryopreservation of CD34⁺ hematopoietic stem cells (HSC) from umbilical cord blood (UCB) were optimized with a new cryo-medium containing 10% ethylene glycol (EG) and 2% dimethyl sulfoxide (Me₂SO) using a controlled-rate freezing (CRF) method. After the cryopreservation of mononuclear cells (MNC) from UCB, recoveries of MNC, CD34⁺ cells, and total colony-forming units (CFU) were significantly improved compared to those in the control cryo-medium containing 10% Me₂SO and 2% Dextran-40 (P < 0.05). This study shows that the new cryo-medium and CRF method provide better recoveries of MNC, HSC and total CFU than the control cryo-medium and isopropylalcohol freezing (IPA) method. Therefore, this cryo-medium, combined with the CRF method, is valuable for optimizing cryopreservation conditions for HSC from UCB to obtain satisfactory HSC recovery.     

Comparison of stem cell viability of bone marrow cryopreserved by two different methods

Two different cryogenic methods were used to study the preservation of murine bone marrow cells. Compared to the classical methods, in which separated mononuclear marrow cells in 10% dimethyl sulfoxide (DMSO) were cryopreserved in liquid nitrogen (-196 degrees C), a modified technique was carried out by cryopreservation of unfractionated marrow cells in a mixed protectant of 5% DMSO and 6% hydroxyethyl starch (HES) at -80 degrees C. Samples that were separately thawed after storage for 1, 4, 8, and 12 weeks were assayed for cell viability and recovery of CFU-GM and CFU-S. No macroscopic clumping of cells was noted either in fractionated or in unfractionated marrow cell cryopreservations. A mild damage, about 25% reduction of stem cells, was found at 1 week and did not deepen further. It seems that the greatest loss of stem cells occurred in the process of cryopreservation itself. Compared to prefreeze values, both a high number of cells that excluded trypan blue (87 +/- 3.4%) and a high recovery of CFU-GM (75 +/- 9.8%) and CFU-S (74 +/- 11.2) were observed in unfractionated marrow samples cryopreserved with the DMSO/HES mixture at -80 degrees C for 3 months and these results were very similar to those obtained from fractionated mononuclear marrow cells cryopreserved at -196 degrees C. The DMSO/HES protectant provides a simplified bone marrow cryopreservation technique that should be favorable to clinical application because of its high stem cell recovery and avoidance of cell-separation manipulation.